Cedarlane Laboratories

Cedarlane Laboratories is a Canadian life-science company focused on products used in biomedical research, immunology, cell biology, and related laboratory applications. The company was incorporated in 1975 by three Canadian researchers associated with the University of Toronto and the Ontario Cancer Institute: Dr. S. Abrahams, Dr. A.J. Farmilo, and R.C. Course. Its origins therefore lie in the supply and development of specialized research materials rather than in consumer healthcare or pharmaceutical prescribing products. Cedarlane manufactures and distributes a range of laboratory products. Its reported manufactured portfolio includes monoclonal antibodies, polyclonal antibodies, cell-separation media, complement products used in tissue-typing work, and immunocolumns. These products support laboratory workflows that require targeted biological reagents, immune-system components, or methods for isolating particular cell populations. The company also markets density-gradient cell-separation media under the Lympholyte trade name and offers cell-line platforms and marker information associated with the CELLutions brand. Such offerings are intended for academic and commercial research programs rather than direct consumer use. A major part of Cedarlane’s business is distribution. The company has reported distributing products on behalf of more than 1,400 life-science manufacturers and handling more than five million products. This distribution role gives Cedarlane a broader commercial position than a single-product biotechnology supplier: it operates as both a producer of selected biological research materials and an intermediary connecting laboratories with a wide range of international manufacturers. Cedarlane expanded its physical presence in the United States when it opened a branch office in Burlington, North Carolina, in 2006. Together with its Canadian base in Burlington, Ontario, this created two principal operating locations in Canada and the United States. The company has been described as a multinational corporation with more than 100 employees across those countries. Its quality and medical-device-related credentials have included registration to ISO 9001:2008 and ISO 13485:2003 standards, as reported in the company’s reference material. The company also developed its Canadian distribution business through an agreement with ATCC. In July 2007, Cedarlane became the exclusive Canadian distributor of ATCC products. Later that year, in November 2007, it acquired CELLutions Biosystems Inc., a company founded by the University of Toronto Innovations Foundation. These moves broadened Cedarlane’s portfolio and strengthened its connection to cell-based research tools and institutional innovation. Beyond commercial operations, Cedarlane has partnered with Canadian charitable organizations to support fundraising and awareness activities. Reported partners have included the Canadian Cancer Society, the Canadian Breast Cancer Foundation, and the SickKids Foundation, alongside organizations associated with children facing economic hardship and men’s health initiatives. Available reference material does not provide sufficient detail to establish the dates, financial amounts, or outcomes of individual programs. Cedarlane’s positioning is that of a specialized, technically oriented supplier for research laboratories. Its value proposition combines proprietary or manufactured reagents, cell-separation and cell-line tools, and a large catalog of distributed products. The available public material does not establish a separate consumer-facing brand architecture, current ownership structure, current executive roster, or detailed recent operating performance. Accordingly, the brand is best characterized as an active Canadian private life-science research-products company with a Canada–United States operating footprint.

Cedarlane Laboratories was incorporated in Canada in 1975 by Dr. S. Abrahams, Dr. A.J. Farmilo, and R.C. Course, three researchers connected with the University of Toronto and the Ontario Cancer Institute. The founding background placed the company close to Canadian academic and cancer-research communities and shaped its focus on specialized laboratory materials rather than consumer health products. Over time, Cedarlane developed a combined manufacturing and distribution model. Its manufactured products have included monoclonal and polyclonal antibodies, cell-separation media, complement products used in tissue-typing work, and immunocolumns. It also became associated with the Lympholyte trade name for density-gradient cell-separation media and with CELLutions offerings involving cell-line platforms and marker information for academic and commercial research programs. The distribution side of the business expanded substantially. Cedarlane has reported distributing more than five million products for over 1,400 global life-science manufacturers. This catalog-based distribution activity complemented its own manufactured products and positioned the company as a supplier capable of serving laboratories across multiple research disciplines. In 2006, Cedarlane opened a United States branch in Burlington, North Carolina. Its principal locations consequently included Burlington, Ontario, and Burlington, North Carolina. The expansion gave the Canadian company a direct presence in the United States and supported its description as a multinational organization with more than 100 employees in Canada and the United States. Public reference material also identifies Cedarlane as registered to ISO 9001:2008 and ISO 13485:2003 standards, reflecting quality-management and medical-device-related processes reported for the business. Cedarlane’s corporate development continued in 2007. In July, it became the exclusive Canadian distributor of products from ATCC, a significant arrangement for a company serving biological and biomedical research laboratories. In November of the same year, Cedarlane acquired CELLutions Biosystems Inc., which had been founded by the University of Toronto Innovations Foundation. The transaction broadened Cedarlane’s connection with cell-line and marker-related research tools and reinforced its relationship with Canadian academic innovation. The company has also undertaken charitable partnerships in Canada. Reported beneficiaries and partners have included the Canadian Cancer Society, the Canadian Breast Cancer Foundation, and the SickKids Foundation. Other activities have supported causes involving economically disadvantaged children and men’s health. The available sources identify the types of causes and organizations but do not provide enough information to document individual campaign dates, contribution amounts, or measurable results. Cedarlane is therefore historically characterized by four connected developments: an academic-research-oriented Canadian foundation, a portfolio of immunology and cell-biology products, expansion into United States operations, and growth as a broad distributor for external life-science manufacturers. The supplied reference material does not document later ownership changes, a public listing, current senior management, or detailed recent product launches. Those areas require further verification.

1. 2007Exclusive ATCC distribution agreement in Canada

   Cedarlane became the exclusive Canadian distributor of ATCC products in July.

   Source
2. 2007CELLutions Biosystems acquisition

   Cedarlane acquired CELLutions Biosystems Inc. in November, expanding its cell-line and marker-related research portfolio.

   Source
3. 2006United States branch established

   The company opened a branch office in Burlington, North Carolina.

   Source
4. 1975Incorporation of Cedarlane Laboratories

   Cedarlane was incorporated by Dr. S. Abrahams, Dr. A.J. Farmilo, and R.C. Course, researchers associated with the University of Toronto and the Ontario Cancer Institute.

   Source

A specialized life-science research supplier combining internally manufactured immunology and cell-biology products with broad distribution services for academic, clinical, and commercial laboratories.

• Monoclonal antibodiesResearch antibodies

  Cedarlane manufactures monoclonal antibodies for laboratory research. These products are designed around highly specific antigen recognition and can support immunology, cell biology, disease-model, and analytical workflows. The supplied sources do not identify individual antibody targets, host systems, or current catalog formulations, so the line is described at the portfolio level rather than as a list of specific reagents.

• Polyclonal antibodiesResearch antibodies

  The company’s reported manufactured portfolio includes polyclonal antibodies, another class of immunological research reagent. Polyclonal products can be used in detection and assay applications where recognition by multiple antibody populations is useful. Available reference material does not provide a complete catalog, target list, or product-level launch chronology.

• LympholyteCell-separation media

  Lympholyte is Cedarlane’s trade name for density-gradient cell-separation media. These products are intended to help laboratories separate cell populations according to density, supporting sample preparation and downstream research in immunology, hematology, and cell biology. The supplied material does not specify the full range of formulations or current availability by market.

• CELLutionsCell-line research platforms

  CELLutions refers to cell-line platforms and related marker information offered for academic and commercial research programs. The portfolio is associated with cell-based experimental systems and information that helps researchers identify or work with particular markers. Cedarlane acquired CELLutions Biosystems Inc. in 2007; detailed current product specifications are not provided in the supplied sources.

• Complement productsImmunology research reagents

  Cedarlane manufactures complement products used in tissue-typing applications and related immunological research. These biological reagents support laboratory procedures involving complement activity and immune compatibility. The available reference does not identify particular source species, formulations, applications beyond tissue typing, or product-level release dates.

• ImmunocolumnsCell and biomolecule separation tools

  Immunocolumns are among Cedarlane’s reported manufactured products. They are specialized laboratory tools that use immunological binding principles in separation or enrichment workflows. The supplied material does not provide technical specifications, named sub-lines, or a complete description of their intended research protocols.

• Cancer research fundraising partnerships

  Canada

  Cedarlane has partnered with Canadian charitable organizations, including the Canadian Cancer Society and the Canadian Breast Cancer Foundation, in activities intended to raise funds or awareness for cancer research.

  Outcome. The available material does not report campaign-specific fundraising totals or outcomes.

  Source
• SickKids Foundation partnership

  Canada

  Cedarlane has been reported as partnering with the SickKids Foundation in support of children’s health-related charitable activity.

  Outcome. No campaign dates, contribution amounts, or quantified results are given in the supplied reference.

  Source
• Children’s and men’s health initiatives

  Canada

  The company has also been associated with charitable initiatives involving economically impoverished children and men’s health causes.

  Outcome. Specific partner organizations, dates, funding levels, and outcomes are not identified in the supplied material.

  Source

• 2007Exclusive Canadian distribution of ATCC productsStrategy

  Cedarlane sought to expand the range of research products available through its Canadian distribution network.

  What changed. In July 2007, Cedarlane became the exclusive distributor of ATCC products in Canada.

  Aftermath. The agreement strengthened Cedarlane’s role as a Canadian channel for external life-science research products.

  Source
• 2007Acquisition of CELLutions BiosystemsM&A

  CELLutions Biosystems was a company founded by the University of Toronto Innovations Foundation and focused on cell-line-related research offerings.

  What changed. Cedarlane acquired CELLutions Biosystems Inc. in November 2007.

  Aftermath. The acquisition added CELLutions cell-line platforms and marker information to Cedarlane’s research-product portfolio.

  Source
• 2006Establishment of a United States branchStrategy

  Cedarlane’s Canadian distribution and manufacturing activities were followed by an expansion into the United States.

  What changed. The company opened a branch office in Burlington, North Carolina.

  Aftermath. The branch became one of the company’s two principal reported locations, alongside Burlington, Ontario.

  Source

• 2007Cedarlane becomes exclusive Canadian distributor for ATCC products

  In July 2007, Cedarlane took on exclusive distribution of ATCC products in Canada.

  Other
  Source
• 2007Cedarlane acquires CELLutions Biosystems

  Cedarlane acquired CELLutions Biosystems Inc. in November 2007, adding a company associated with the University of Toronto Innovations Foundation to its portfolio.

  M&A
  Source
• 2006Cedarlane opens a United States branch in Burlington, North Carolina

  Cedarlane established a branch office in Burlington, North Carolina, expanding its operating presence beyond Canada.

  Other
  Source

1. Cedarlane Laboratories
2. Cedarlane Laboratories official website